Live
- Bad weather: 15 flights diverted, over 100 delayed
- Raj HC stays posting of sub-inspectors
- AP, TG move forward to settle bifurcation issues
- Govt abolishes two-child norm for local body candidates
- Warangal to reverberate with ‘Praja Palana Vijayotsavalu’
- MyVoice: Views of our readers 19th November 2024
- Aurobindo under fire over 108 services
- CPI demands house sites for landless poor
- No shortage of DAP: Haryana CM assures Assembly
- Why Indian pollsters should step back
Natco Pharma launches blood cancer drug
Highlights
Natco Pharma on Wednesday announced the launch of a blood cancer drug in the domestic market. The new drug is priced in the range of Rs 5,000-Rs 20,000, which is a 98 per cent lower than what it is sold in the US market.
Hyderabad: Natco Pharma on Wednesday announced the launch of a blood cancer drug in the domestic market. The new drug is priced in the range of Rs 5,000-Rs 20,000, which is a 98 per cent lower than what it is sold in the US market.
- Available at 98% discounted price than US mkt
Natco Pharma has launched a generic version of pomalidomide 1 mg, 2 mg, and 4 mg capsules in India, the drug major said in a communiqué to the BSE. Pomalidomide is for patients with multiple myeloma (a type of blood cancer). Natco has priced its generic medicine 1 mg, 2 mg, and 4 mg capsules at Rs 5,000, Rs 10,000 Rs 20,000 respectively for a monthly pack of 21 capsules.
Next Story
ADVERTISEMENT
